BSG and urinary bladder carcinoma: CD147-sEVs have been identified in ovarian and bladder cancer, and recent evidence suggests that circulating CD147-containing EVs might be used as a biomarker to monitor response to therapy in CRC patients, but no study so far has analyzed the CD147 fate during colorectal cancer stem cell lines (CR-CSCs) differentiation [13,14,15,16].